

OPTICERA - Identification of factors allowing a therapeutic anemia management optimization in CKD patients treated with C.E.R.A.

Head :Roche Medical data center

Last update : 11/26/2021 | Version : 1 | ID : 74090

General

Identification

Detailed name Identification of factors allowing a therapeutic anemia management optimization in CKD patients treated with C.E.R.A.

Sign or acronym OPTICERA

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation

ML39300

General Aspects

Medical area Urology, andrology and nephrology

Study in connection with Covid-19 No

Pathology (details) Anemia in Chronic Kidney Disease

Health determinants Medicine

Keywords Méthoxy-polyéthylène glycol-époétine bêta

Scientific investigator(s) (Contact)

Name of the director Roche Medical data center

Address 4 cours de l'Île Seguin - 92100 Boulogne-Billancourt

Email data_sharing.france@roche.com

Organization Roche SAS

Collaborations

Participation in projects, No

Funding

Funding status	Private
----------------	---------

Governance of the database

Sponsor(s) or organisation(s) responsible	Roche SAS
---	-----------

Organisation status	Private
---------------------	---------

Presence of scientific or steering committees	Yes
---	-----

Additional contact

Main features

Type of database

Type of database	Study databases
------------------	-----------------

Study databases (details)	Longitudinal study (except cohorts)
---------------------------	-------------------------------------

Database recruitment is carried out by an intermediary	A selection of health care professionals
--	--

Database recruitment is made on the basis of:	Medication(s) taken
---	---------------------

Database recruitment is carried out as part of an interventional study	No
--	----

Database objective

Main objective	Primary Objective: To identify the potential factors of optimizing the therapeutic management of renal anemia with C.E.R.A. Secondary Objectives: - Analysis of the therapeutic response to C.E.R.A., according to 4 definitions (reach or maintenance of the Hb concentration within the therapeutic target range of [10-12] g/dL, limitation of Hb variability at +/- 1 g/dL from the baseline value, both above criteria, or at least one of the above criteria, after a 3-month treatment period) - Description of patient and disease characteristics at first C.E.R.A. injection - Description of the evolution of CKD management (physical examination, laboratory parameters)
----------------	---

including Hb values and renal function, prior and ongoing concomitant treatments for anemia, as well as concomitant diseases and treatments) under C.E.R.A. treatment

- Search for any associations/correlations between variables and detection of particular profiles.

Inclusion criteria	Inclusion criteria: - CKD patients having started C.E.R.A. treatment at inclusion - With at least one Hb value within the 3-month period prior to the first C.E.R.A. injection - With no participation in an interventional study
Population type	
Age	- Adulthood (19 to 24 years) - Adulthood (25 to 44 years) - Adulthood (45 to 64 years) - Elderly (65 to 79 years) - Great age (80 years and more)
Population covered	Sick population
Pathology	D63 - Anaemia in chronic diseases classified elsewhere
Gender	- Male - Woman
Geography area	National
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2009
Date of last collection (YYYY or MM/YYYY)	2015
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	2984
Data	
Database activity	Data collection completed

Type of data collected	Clinical data
Clinical data (detail)	Medical registration
Details of collected clinical data	Pooling of 5 non-interventional studies with Mircera® (OCEANE / HORTENSIA / COMETE / PERCEPOLIS / MIRIADE). Type of data collected : demographics, comorbidities, CKD history, prior treatments for anemia, laboratory data, first C.E.R.A. injection, other treatments, vital signs, treatment for anemia, C.E.R.A. injections, other treatments, early withdrawal.
Presence of a biobank	No
Procedures	
Data collection method	Pool of 5 non interventional databases
Classifications used	CDISC like
Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Followed pathology	N18 - Chronic kidney disease
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Dedicated website	https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html
Presence of document that lists variables and coding procedures	Yes
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only